Login to Your Account



Profitability is in sight for Admedus with Vascucel approval

By Tamra Sami
Staff Writer

Monday, October 17, 2016

PERTH, Australia – With another FDA approval in hand for its regenerative tissue portfolio, Brisbane, Australia-based Admedus Ltd. said it expects to become profitable in the next 12 to 18 months.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription